Trial · NCT02097277
Results by group72
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 72
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12 | Treatment A: Placebo | 0.0005 | Standard Deviation 0.00622 | Percent Change | |
| Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12 | Treatment B: BMS-986036 (1 mg Daily) | 0.0029 | Standard Deviation 0.00882 | Percent Change | |
| Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12 | Treatment C: BMS-986036 (5 mg Daily) | 0.0007 | Standard Deviation 0.00692 | Percent Change | |
| Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12 | Treatment D: BMS-986036 (20 mg Daily) | 0.0004 | Standard Deviation 0.00814 | Percent Change | |
| Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12 | Treatment E: BMS-986036 (20 mg Weekly) | -0.0004 | Standard Deviation 0.00418 | Percent Change | |
| Change in Body Weight From Baseline to Week 12 | Treatment A: Placebo | -0.22 | Standard Deviation 2.615 | Kilogram | |
| Change in Body Weight From Baseline to Week 12 | Treatment B: BMS-986036 (1 mg Daily) | -0.26 | Standard Deviation 1.718 | Kilogram | |
| Change in Body Weight From Baseline to Week 12 | Treatment C: BMS-986036 (5 mg Daily) | -0.10 | Standard Deviation 2.883 | Kilogram | |
| Change in Body Weight From Baseline to Week 12 | Treatment D: BMS-986036 (20 mg Daily) | -1.09 | Standard Deviation 2.583 | Kilogram | |
| Change in Body Weight From Baseline to Week 12 | Treatment E: BMS-986036 (20 mg Weekly) | -0.50 | Standard Deviation 2.297 | Kilogram | |
| Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Composite Index of Insulin Sensitivity (CISI) (Matsuda Index) | Treatment A: Placebo | -0.18 | Standard Deviation 0.967 | Unit on a scale | |
| Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Composite Index of Insulin Sensitivity (CISI) (Matsuda Index) | Treatment B: BMS-986036 (1 mg Daily) | -0.19 | Standard Deviation 1.348 | Unit on a scale | |
| Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Composite Index of Insulin Sensitivity (CISI) (Matsuda Index) | Treatment C: BMS-986036 (5 mg Daily) | -0.18 | Standard Deviation 2.102 | Unit on a scale | |
| Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Composite Index of Insulin Sensitivity (CISI) (Matsuda Index) | Treatment D: BMS-986036 (20 mg Daily) | 0.77 | Standard Deviation 2.455 | Unit on a scale | |
| Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Composite Index of Insulin Sensitivity (CISI) (Matsuda Index) | Treatment E: BMS-986036 (20 mg Weekly) | 0.54 | Standard Deviation 1.772 | Unit on a scale | |
| Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | Treatment A: Placebo | -0.19 | Standard Deviation 4.136 | Unit on a Scale | |
| Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | Treatment B: BMS-986036 (1 mg Daily) | 0.00 | Standard Deviation 5.633 | Unit on a Scale | |
| Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | Treatment C: BMS-986036 (5 mg Daily) | -1.88 | Standard Deviation 8.940 | Unit on a Scale | |
| Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | Treatment D: BMS-986036 (20 mg Daily) | -1.73 | Standard Deviation 4.589 | Unit on a Scale | |
| Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | Treatment E: BMS-986036 (20 mg Weekly) | -0.34 | Standard Deviation 3.707 | Unit on a Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02097277/results